Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Brian P. Doehle"'
Publikováno v:
Human Gene Therapy. 32:21-30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aad62987e90f0ae82e67c121d6789f0e
https://doi.org/10.1089/hum.2020.252
https://doi.org/10.1089/hum.2020.252
Autor:
Devi SenGupta, Pottage John C, Moses Supercharger Nsubuga, Thumbi Ndung'u, Timothy Attoye, Mitchell Warren, David Ripin, Rowena Johnston, Karine Dubé, Brian P. Doehle, Izukanji Sikazwe, Mark Dybul, Joseph M. McCune, Sharon R Lewin, Rosanne Lamplough, Steven G. Deeks, Cathy Bansbach, James F. Rooney, Adam Jiang, Gary J Nabel
Publikováno v:
Lancet HIV
The Lancet. HIV
The Lancet. HIV
Summary Developing a cure for HIV is a global priority. Target product profiles are a tool commonly used throughout the drug development process to align interested parties around a clear set of goals or requirements for a potential product. Three di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33c2cdfcacf051134bea836828eff520
https://doi.org/10.1016/s2352-3018(20)30234-4
https://doi.org/10.1016/s2352-3018(20)30234-4
Autor:
Steven G. Deeks, Brian P. Doehle, Lauren Mathae, Solange Baptiste, Murray Lumpkin, Holly L. Peay, Carl W. Dieffenbach, Thumbi Ndung'u, Adam Jiang, Timothy Attoye, François Dabis, Sharon R Lewin, Pottage John C, Izukanji Sikazwe, Mark Dybul, Mitchell Warren, Joseph M. McCune, Dominic Kemps, Maureen M Goodenow, Peter Cherutich, Moses Supercharger Nsubuga
Publikováno v:
Lancet HIV
The Lancet. HIV
The Lancet. HIV
Summary In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8e2ef5178c066a0f35e06d8aa48244f
https://doi.org/10.1016/s2352-3018(20)30232-0
https://doi.org/10.1016/s2352-3018(20)30232-0
Autor:
Emily H. Turner, Cameron C. Trenor, Susan C. Stevenson, Jonathan M. Spector, Brian P. Doehle, Joseph M. McCune
Publikováno v:
Mol Ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::244f65f0a9da4e4334d91db568e92dff
https://europepmc.org/articles/PMC8571166/
https://europepmc.org/articles/PMC8571166/
Autor:
Julia Lu, Simin Xu, Gregory Camus, Brian P. Doehle, Mei Yu, Bin Han, Guofeng Cheng, Michael D. Miller, Hadas Dvory-Sobol, Hongmei Mo
Publikováno v:
Virology. 514:134-141
Hepatitis C Virus (HCV) is a diverse human pathogen which displays ~15% divergence at the subtype level. To facilitate development of antivirals with pan-genotype activity, we developed the first genotype 4d subgenomic replicon, as well as new replic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b65b5027c4b5ec0cc8d9cdb563f7f4
https://doi.org/10.1016/j.virol.2017.11.003
https://doi.org/10.1016/j.virol.2017.11.003
Autor:
Charlotte Hedskog, Ming Lin, Evguenia S. Svarovskaia, Ronald Nahass, Eric Lawitz, Ziad Younes, Diana M. Brainard, Michael P. Ryan, Catherine A.M. Stedman, John G. McHutchison, Hadas Dvory-Sobol, Hongmei Mo, Edward Gane, Mark S. Sulkowski, Jenny C. Yang, Brian P. Doehle, Sophie Metivier
Publikováno v:
Hepatology Communications
S282T in NS5B is the primary amino acid substitution associated with resistance to sofosbuvir (SOF) but has rarely been detected in patients treated with a SOF-based regimen. Here, the emergence and fitness of the S282T substitution in virologic fail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e15a515d3dbaecb6ea354970814db2b5
https://doi.org/10.1002/hep4.1060
https://doi.org/10.1002/hep4.1060
Autor:
Masashi Mizokami, Alessandra Mangia, John G. McHutchison, Wan-Long Chuang, Chohee Yun, Kwang Hyub Han, Evguenia S. Svarovskaia, Ross Martin, Diana M. Brainard, Ira M. Jacobson, Hadas Dvory-Sobol, Gregory J. Dore, Stephen Pianko, Charlotte Hedskog, Hongmei Mo, Michael D. Miller, Brian P. Doehle, Mark S. Sulkowski, Stefan Zeuzem, Steven J. Knox
Publikováno v:
Journal of Hepatology. 66:910-918
Background & Aims The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated substitutions (RASs). We analyzed data from 35 phase I, II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adc2ec97a2d8cddacaae1b3551bb8082
https://doi.org/10.1016/j.jhep.2017.01.007
https://doi.org/10.1016/j.jhep.2017.01.007
Autor:
Diana M. Brainard, Kris V. Kowdley, Michael D. Miller, Eric Lawitz, Brian P. Doehle, Evguenia S. Svarovskaia, Ross Martin, Hongmei Mo, Nezam H. Afdhal, David L. Wyles, Hadas Dvory-Sobol, Edward Gane
Publikováno v:
Journal of Hepatology. 66:703-710
Background & Aims Ledipasvir/sofosbuvir combination treatment in phase III clinical trials resulted in sustained viral suppression in 94–99% of patients. This study characterized drug resistance in treatment failures, which may help to inform retre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c75309a0ec837761d50e86825183b84
https://doi.org/10.1016/j.jhep.2016.11.022
https://doi.org/10.1016/j.jhep.2016.11.022
Autor:
Diana M. Brainard, Shyam Kottilil, Peter Ruane, Eric S. Daar, Susanna Naggie, Mark S. Sulkowski, David L. Wyles, John McNally, Erik Mogalian, K.C. Huang, Kimberly A. Workowski, Anu Osinusi, John G. McHutchison, Norbert Bräu, Brian P. Doehle, Anne F Luetkemeyer, Oluwatoyin Adeyemi, Arthur Y. Kim
Publikováno v:
Clinical Infectious Diseases. 65:6-12
Background A safe, simple, effective, and pan-genotypic regimen to treat hepatitis C virus (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains a medical need. We assessed the efficacy and safety of the NS5B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2500313e9881d6880e2df3132b047ac8
https://doi.org/10.1093/cid/cix260
https://doi.org/10.1093/cid/cix260
Autor:
Subrat K. Acharya, Abhijit Chowdhury, Ajay Duseja, B. Kanwar, Kaushal Madan, R. Mehta, Brian P. Doehle, R. Pawan, Mohan Prasad, Akash Shukla, Shiv Kumar Sarin, Mani Subramanian, Ajit Sood, Evguenia S. Svarovskaia, K. Kersey, Randhir Sud, Sandeep Nijhawan, Abraham Koshy, Samir Shah, Deyuan Jiang, Dharmesh Kapoor
Publikováno v:
Journal of Viral Hepatitis. 24:371-379
Summary Until 2014, pegylated interferon plus ribavirin was the recommended standard of care for the treatment of chronic hepatitis C virus (HCV) infection in India. This open-label phase 3b study, conducted across 14 sites in India between 31 March
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b207cce3e325a0db882c371f9817810c
https://doi.org/10.1111/jvh.12654
https://doi.org/10.1111/jvh.12654